This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/518913-curevac-vaccine-effective-south-african-variant/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| CureVac Covid-19 vaccine shows 100% protection against South African variant in 'first of its kind' mouse study | CureVac Covid-19 vaccine shows 100% protection against South African variant in 'first of its kind' mouse study |
| (30 days later) | |
| The Covid-19 jab made by German biopharmaceutical firm CureVac has shown full protection against the South African coronavirus variant and the original form of the virus, according to the results of a preprint study on mice. | The Covid-19 jab made by German biopharmaceutical firm CureVac has shown full protection against the South African coronavirus variant and the original form of the virus, according to the results of a preprint study on mice. |
| Covid-infected mice that were vaccinated demonstrated "robust antibody responses" and developed complete protection against the virus, with a 100% survival rate, researchers said. | Covid-infected mice that were vaccinated demonstrated "robust antibody responses" and developed complete protection against the virus, with a 100% survival rate, researchers said. |
| The animals were deliberately exposed to the B.1.351 strain of Covid – known as the South African variant – as well as the original form of the virus as part of a preclinical challenge infection study. | The animals were deliberately exposed to the B.1.351 strain of Covid – known as the South African variant – as well as the original form of the virus as part of a preclinical challenge infection study. |
| German researchers gave the mice two doses of the mRNA-based CureVac jab 28 days apart and found that it "efficiently" blocked and reduced the replication of the virus in the animals. | German researchers gave the mice two doses of the mRNA-based CureVac jab 28 days apart and found that it "efficiently" blocked and reduced the replication of the virus in the animals. |
| The study, published in preprint format, used ACE2-transgenic mice, which are common in Covid-19 vaccine research as they exhibit similar responses to humans when infected with the virus. | The study, published in preprint format, used ACE2-transgenic mice, which are common in Covid-19 vaccine research as they exhibit similar responses to humans when infected with the virus. |
| CureVac's chief scientific officer, Igor Splawski, said that the risk of more infectious coronavirus variants like B.1.351 pose a major threat to global immunization efforts. | CureVac's chief scientific officer, Igor Splawski, said that the risk of more infectious coronavirus variants like B.1.351 pose a major threat to global immunization efforts. |
| "To our knowledge, this is the first challenge study in a human ACE2 transgenic mouse model of severe disease that shows complete protection against one of the most threatening virus variants," he said. | "To our knowledge, this is the first challenge study in a human ACE2 transgenic mouse model of severe disease that shows complete protection against one of the most threatening virus variants," he said. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |